Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 31722-674

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 31722-674). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Camber1. (Camber1)

FDA Label Image

Sacubitrilandvalsartantablets24mg26mg60s (Sacubitrilandvalsartantablets24mg26mg60s)

Sacubitril and Valsartan 24 mg/26 mg film-coated tablets packaging label from Camber Pharmaceuticals, Inc. The label states the dosage strength, contains 60 tablets, and includes storage instructions at 20° to 25°C (68° to 77°F). It provides a U.S. contact number and manufacturing information indicating it is made for Camber Pharmaceuticals, Inc., Piscataway, NJ, by Hetero Labs Limited, Hyderabad, India.*

FDA Label Image

Sacubitrilandvalsartantablets49mg51mg60s (Sacubitrilandvalsartantablets49mg51mg60s)

Label for Sacubitril and Valsartan Tablets 49 mg/51 mg, film-coated tablets. The label indicates the product is manufactured for Camber Pharmaceuticals, Inc., Piscataway, NJ, with a quantity of 60 tablets and Rx only. Storage instructions and contact information are also shown.*

FDA Label Image

Sacubitrilandvalsartantablets97mg103mg60s (Sacubitrilandvalsartantablets97mg103mg60s)

Label for Sacubitril and Valsartan tablets, film-coated, with a strength of 97 mg sacubitril and 103 mg valsartan per tablet. The label indicates a package containing 60 tablets. Manufactured for Camber Pharmaceuticals, Inc., Piscataway, NJ, and produced by Hetero Labs Limited, Hyderabad, India. Storage instructions and contact information are included.*

FDA Label Image

Sacubitrilandvalsartantabletsfigure1 (Sacubitrilandvalsartantabletsfigure1)

A chart depicting the geometric mean ratio and 90% confidence intervals for various coadministered drugs relative to a reference. The x-axis represents change relative to reference, ranging from 0.5 to 2. Drugs listed on the y-axis include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. Two data series are shown with different markers representing AUC and Cmax values.*

FDA Label Image

Sacubitrilandvalsartantabletsfigure2 (Sacubitrilandvalsartantabletsfigure2)

A forest plot chart showing geometric mean ratios and 90% confidence intervals for AUC and Cmax parameters comparing LBQ657 and valsartan across different population subgroups. The chart contrasts changes relative to a reference in categories such as renal and hepatic impairment, age, sex, and race, with separate markers for LBQ657 and valsartan. The plots visualize pharmacokinetic variability in these populations.*

FDA Label Image

Sacubitrilandvalsartantabletsfigure3 (Sacubitrilandvalsartantabletsfigure3)

Three Kaplan-Meier curves display time to clinical events in PARADIGM-HF comparing Sacubitril and Valsartan versus Enalapril. Figure A shows cumulative failure rates for cardiovascular death or heart failure hospitalizations; Figure B depicts cardiovascular death only; Figure C covers heart failure hospitalizations. Each graph includes patient numbers at risk over time and hazard ratios with confidence intervals.*

FDA Label Image

Sacubitrilandvalsartantabletsfigure4 (Sacubitrilandvalsartantabletsfigure4)

A forest plot chart showing hazard ratios with 95% confidence intervals comparing Sacubitril and Valsartan versus Enalapril across various patient subgroups. Subgroups include age ranges, gender, weight, race, region, disease classifications, estimated glomerular filtration rate (GFR), diabetes status, blood pressure, ejection fraction, atrial fibrillation presence, NT-pro BNP levels, hypertension status, and prior use of ACE inhibitors. The chart visually represents relative outcomes with squares and confidence interval lines along a scale ranging from 'Sacubitril and Valsartan Better' to 'Enalapril Better.'*

FDA Label Image

Sacubitrilandvalsartantabletsfigure41 (Sacubitrilandvalsartantabletsfigure41)

A forest plot displaying hazard ratios with 95% confidence intervals comparing Sacubitril and Valsartan versus Enalapril across various subgroups, including prior use of ARB, aldosterone antagonist, hospitalization for heart failure, time since diagnosis, cause of heart failure, and presence of an ICD device. The plot visually represents the comparative effectiveness of the two treatments.*

FDA Label Image

Sacubitrilandvalsartantabletsstructure (Sacubitrilandvalsartantabletsstructure)

Chemical structure of sacubitril and valsartan sodium salt, illustrating the molecular arrangement of both active ingredients in the tablet formulation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.